Senfei Pharmaceutical Technology

Senphi Pharmaceutical is a Shanghai-based biotechnology company specializing in the development of next-generation small molecule therapeutics, with a core focus on targeted protein degradation (PROTAC) technology. The company leverages its proprietary platform to design bifunctional molecules that recruit E3 ubiquitin ligases to degrade disease-causing proteins, particularly in the field of oncology. Senphi's pipeline includes programs targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer. By addressing targets previously considered undruggable, the company aims to overcome resistance mechanisms associated with traditional inhibitors. Senphi is positioned as an innovative player in the rapidly evolving landscape of protein degradation therapy in China.